You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment

Authors

  • Mélanie Desbois Analyse Moléculaire, Modélisation et Imagerie de la Maladie Cancéreuse, Laboratoire d’Immunomonitoring en Oncologie, Gustave Roussy Institute, INSERM, CNRS, Paris-Saclay University, Villejuif, Île-de-France, France Cytune Pharma, Nantes, France Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, Île-de-France, France PubMed articlesGoogle scholar articles
  • Coralie Béal Centre d’investigation Clinique Biothérapie 1428, Gustave Roussy Institute, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Mélinda Charrier Analyse Moléculaire, Modélisation et Imagerie de la Maladie Cancéreuse, Laboratoire d’Immunomonitoring en Oncologie, Gustave Roussy Institute, INSERM, CNRS, Paris-Saclay University, Villejuif, Île-de-France, France Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, Île-de-France, France Centre d’investigation Clinique Biothérapie 1428, Gustave Roussy Institute, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Benjamin Besse Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, Île-de-France, France Comité de Pathologie Thoracique, Gustave Roussy Institute, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Guillaume Meurice Plateforme de Bioinformatique, Gustave Roussy Institute, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Nicolas Cagnard Plateforme de Bioinformatique, Université Paris Descartes, Paris, Île-de-France, France PubMed articlesGoogle scholar articles
  • Yannick Jacques U1232, CRCINA, Nantes, Pays de la Loire, France PubMed articlesGoogle scholar articles
  • David Béchard Cytune Pharma, Nantes, France PubMed articlesGoogle scholar articles
  • Lydie Cassard Analyse Moléculaire, Modélisation et Imagerie de la Maladie Cancéreuse, Laboratoire d’Immunomonitoring en Oncologie, Gustave Roussy Institute, INSERM, CNRS, Paris-Saclay University, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Nathalie Chaput Analyse Moléculaire, Modélisation et Imagerie de la Maladie Cancéreuse, Laboratoire d’Immunomonitoring en Oncologie, Gustave Roussy Institute, INSERM, CNRS, Paris-Saclay University, Villejuif, Île-de-France, France Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France PubMed articlesGoogle scholar articles
  1. Correspondence to Pr Nathalie Chaput; CHAPUT-GRAS.nathalie{at}gustaveroussy.fr
View Full Text

Citation

Desbois M, Béal C, Charrier M, et al
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
Journal for ImmunoTherapy of Cancer 2020;8:e000632. doi: 10.1136/jitc-2020-000632

Publication history

  • Accepted April 7, 2020
  • First published June 12, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.